Novel multiplex bead-based assay with LNA-modified probes for detection of MPL exon 10 mutations

Leukemia Research

Volumn 35, Issue 8, 2011, Pages 1120-1123

  Ivanova, Milena I ^a   Shivarov, Velizar S ^a   Hadjiev, Evgueniy A ^b   Naumova, Elissaveta J ^a  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^b National Hematology Hospital   (Bulgaria)

Author keywords

Bead based assay; LNA; Luminex; MPL exon 10 mutations; Myeloproliferative neoplasms

Indexed keywords

GENOMIC DNA; LOCKED NUCLEIC ACID; PLASMID DNA; THROMBOPOIETIN RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; EXON; GENETIC ASSOCIATION; HUMAN; MOLECULAR PATHOLOGY; MULTIPLEX BEAD BASED LIQUID ASSAY; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; OLIGONUCLEOTIDE PROBE; PLASMID; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; THROMBOCYTHEMIA; VALIDATION PROCESS;

CLINICAL LABORATORY TECHNIQUES; EXONS; HUMANS; MUTATION; MYELOPROLIFERATIVE DISORDERS; OLIGONUCLEOTIDES; PHILADELPHIA CHROMOSOME; RECEPTORS, THROMBOPOIETIN;

EID: 79960236079     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.04.012     Document Type: Article

References (14)

1. Levine R.L., Gilliland D.G. Myeloproliferative disorders. Blood 2008, 112:2190-2198.
2. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138.
3. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3:e270.
4. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
5. Boyd E.M., Bench A.J., Goday-Fernández A., Anand S., Vaghela K.J., Beer P., et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 2010, 149:250-257.
6. Zhuge J., Zhang W., Zhang W., Xu M., Hoffman R. Sensitive detection of MPLW515L/K mutations by amplification refractory mutation system (ARMS)-PCR. Clin Chim Acta 2010, 411:122-123.
7. Pancrazzi A., Guglielmelli P., Ponziani V., Bergamaschi G., Bosi A., Barosi G., et al. A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn 2008, 10:435-441.
8. Dunbar S.A. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta 2006, 363:71-82.
9. Kurreck J., Wyszko E., Gillen C., Erdmann V.A. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 2002, 30:1911-1918.
10. Ghaderi M., Stromberg O., Porwit A. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders. Int J Lab Hematol 2010, 32:122-126.
11. Ruan G.R., Jiang B., Li L.D., Niu J.H., Li J.L., Xie M., et al. MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes. Hematol Oncol 2010, 28:33-39.
12. Paradis F.W., Simard R., Gaudet D. Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology. BMC Med Genet 2010, 11:54.
13. Tefferi A. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. Leuk Lymphoma 2010, 51:576-582.
14. Kristensen L.S., Daugaard I.L., Christensen M., Hamilton-Dutoit S., Hager H., Hansen L.L. Increased sensitivity of KRAS mutation detection by high-resolution melting analysis of COLD-PCR products. Hum Mutat 2010, 31:1366-1373.